Track: Hypertension and Renal Cardiovascular Interactions
Hypertension affects 1.28 billion adults worldwide and remains the single largest modifiable cardiovascular risk factor, yet global blood pressure control rates remain below 25%. The Hypertension & Hypertensive Heart Disease session examines the renal denervation resurgence following SPYRAL and RADIANCE sham-controlled trials, the new drug class of aldosterone synthase inhibitors (lorundrostat, baxdrostat) in resistant hypertension, zilebesiran, an RNA interference antihypertensive agent showing sustained BP reduction from twice-yearly dosing ambulatory BP monitoring in diagnosis, LVH regression strategies in hypertensive heart disease, and the distinct management challenges of hypertension in pregnancy and preeclampsia.
Key Discussion Areas:
- Renal denervation: SPYRAL and RADIANCE trial evidence and current indications
- Aldosterone synthase inhibitors (lorundrostat, baxdrostat) in resistant hypertension
- Zilebesiran: RNA interference antihypertensive therapy Phase II/III data
- Ambulatory and home blood pressure monitoring in diagnosis and management
- Hypertensive heart disease: LVH regression and diastolic dysfunction management
- Resistant and refractory hypertension: diagnostic workup and therapeutic algorithms
- Hypertension in pregnancy: preeclampsia, HELLP, and postpartum cardiovascular risk
- SGLT2 inhibitors in hypertension and cardiorenal protection
Why Attend This Session?
Hypertension specialists, cardiologists, nephrologists, obstetricians, and general physicians will gain updated insights into guideline-concordant BP management, device therapy evidence, emerging pharmacological agents, and the cardiovascular consequences of poorly controlled hypertension across diverse clinical settings.
Related Topics:
- Preventive Cardiology & Cardiovascular Risk Reduction
- Heart Failure & Cardiomyopathies
- Cardiorenal Syndrome & Nephrocardiology
- Women's Heart Health
- Cardiometabolic Syndrome
Frequently Asked Questions:
1.What is the importance of hypertension and renal cardiovascular interactions in cardiovascular medicine?
Hypertension and Renal Cardiovascular Interactions plays a significant role in improving diagnosis, treatment strategies, patient outcomes, and clinical decision-making in modern cardiology.
2.What are the latest trends in hypertension and renal cardiovascular interactions?
Recent trends include precision medicine, AI-assisted diagnostics, minimally invasive therapies, digital healthcare technologies, and personalized patient management.
Scientific Highlights
- Preventive Cardiology and Cardiovascular Risk Reduction
- Heart Failure and Advanced Cardiac Therapies
- Interventional Cardiology and Structural Heart Disease
- Cardiac Electrophysiology and Arrhythmia Management
- Acute Coronary Syndromes
- Cardiovascular Imaging and Multimodality Diagnostics
- Cardiomyopathies: Genetics, Phenotyping, and Treatment
- Cardio Oncology
- Cardiometabolic Disease, Lipidology, and Atherosclerosis
- Hypertension and Renal Cardiovascular Interactions
- Digital Health, AI, and the Future of Cardiology
- Pediatric and Congenital Cardiology
- Vascular Medicine and Aortic Diseases
- Women's Cardiovascular Health and Sports Cardiology
- Precision Medicine, Genomics, and Regenerative Cardiology
- Cardiovascular and Cardiothoracic Surgery
- Cardiovascular Case Studies and Clinical Insights
- Emergency and Critical Cardiac Care
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Conference Enquiry - Kristina Pierce
kristinapierce@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
cardiacsurgery@scientexevents.org
Our Social Presence
Call us at
USA : (+1) 272 374 1068